Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/CIRCIMAGING.124.017967 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of [Ga]Ga-Fibroblast Activation Protein Inhibitor-04 and [F]FDG PET Imaging for Solitary Fibrous Tumor and Preliminary Application of FAP-Targeted Radiopharmaceutical Therapy.
J Nucl Med
March 2025
Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore;
Solitary fibrous tumor (SFT) is a rare sarcoma of mesenchymal origin. Although generally benign, SFTs carry the risk of recurrence and metastasis, with limited effective treatment options. The aims of this study are to compare the performance of fibroblast activation protein inhibitor (FAPI), [Ga]Ga-DOTA-FAPI-04 (denoted as [Ga]Ga-FAPI-04), and conventional [F]FDG PET/CT in patients with recurrent or metastatic SFTs head to head and to preliminarily explore the value of FAP-targeted radiopharmaceutical therapy with Lu for SFT patients.
View Article and Find Full Text PDFExploration of Ga-FAPI-04 PET/MR in Chronic Type B Aortic Dissection.
Circ Cardiovasc Imaging
March 2025
Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China. (C.H., Y.Z., S.Q., Z.L., W.F., L.W.).
Ga-FAPI-04 PET/CT Imaging for Assessing Renal Tubulointerstitial Fibrosis in Lupus Nephritis.
J Nucl Med
March 2025
Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;
The objective of this study was to evaluate the feasibility of using Ga-labeled fibroblast activation protein inhibitor-04 (Ga-FAPI-04) PET/CT imaging as a molecular tracer and noninvasive tool for assessing active renal tubulointerstitial fibrosis in patients with lupus nephritis (LN). The study included 29 LN patients who underwent Ga-FAPI-04 PET/CT scanning to quantify Ga-FAPI-04 uptake. Renal biopsies were performed within a week of scanning.
View Article and Find Full Text PDFDual-Time Point 68 Ga-FAPI-04 PET/CT Improves Tumor Delineation and Cervical Lymph Node Metastasis Identification in Patients With Head and Neck Squamous Cell Carcinoma.
Clin Nucl Med
March 2025
From the Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Purpose: The purpose of this study was to evaluate the benefit of dual-time point 68 Ga-FAPI-04 PET/CT in staging head and neck squamous cell carcinoma (HNSCC).
Patients And Methods: Sixty-nine treatment-naive patients with HNSCC were enrolled. Each patient underwent whole-body 68 Ga-FAPI-04 PET/CT at approximately 30 minutes postinjection and a delayed scan in head and neck region at 2 hours.
Clinical Explorations of [Ga] Ga-FAPI-04 and [F] FDG Dual-Tracer Total-body PET/CT and PET/MR Imaging.
Semin Nucl Med
November 2024
Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Institute of Medical Imaging, Shanghai, China; Institute of Nuclear Medicine, Fudan University, Shanghai, China; Cancer Prevention and Treatment Center, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address:
Fibroblast activation protein inhibitor (FAPI) and [F]fluorodeoxyglucose ([F]FDG) provide complementary biological information, and FAPI/FDG dual-tracer imaging clinical application is increasing recently. However, optimal protocols for FAPI/FDG dual-tracer positron emission tomography/computed tomography (PET/CT) and PET/magnetic resonance (PET/MR) imaging are still under investigation. Due to its high sensitivity, total-body PET/CT allows for imaging with minimal tracer activity and supports the creation of new dual-tracer PET/CT imaging protocols.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!